Ad Header



The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

Company founded by Shkreli off the hook in $43 million lawsuit: judge

Vyera Pharmaceuticals – formerly known as Turing Pharmaceuticals – does not have to pay Impax Laboratories $43 million in a dispute stemming from Turing founder Martin Shkreli’s decision to boost by 5,000 percent the price of a drug Turing bought from Impax, a U.S. judge ruled.

Read More »

U.S. invests in late-stage Ebola vaccines, drugs

The U.S. government is investing more than $170 million to help two new vaccines against Ebola and two Ebola drugs complete the steps needed for FDA approval.

Read More »

Stopping aspirin therapy may raise heart attack, stroke risk

Stopping low-dose aspirin therapy without good reason raises the likelihood of heart attack or stroke by nearly 40 percent, a large Swedish study suggests.

Read More »

FDA approves fast-acting insulin Fiasp

The U.S. Food and Drug Administration approved Novo Nordisk’s fast-acting insulin to treat diabetes.

Read More »

Bay Area’s Zogenix Explodes on Late-Stage Epilepsy Data

Shares of Zogenix Inc. more than doubled following the company’s announcement that its investigational Dravet syndrome drug met its primary endpoints in cutting seizure rates in juvenile patients.

Read More »

Almirall Discontinues R&D for Two Drugs in the U.S.

Almirall SA announced it plans to halt all research into P3058 (onychomycosis) and P3073 (nail psoriasis) in the U.S. However, clinical trials planned in Europe will continue as scheduled.

Read More »

Merck & Co. Terminates Hep C Development Programs

Following a review of Phase II efficacy data and a scan of the “evolving marketplace,” Merck & Co. announced that the company was terminating two hepatitis C programs.

Read More »

Roche’s Perjeta regimen gets FDA priority review

The U.S. FDA granted priority review for Roche’s Perjeta in combination with Herceptin and chemotherapy for treating HER2-positive early breast cancer after surgery.

Read More »

Eli Lilly wins U.S. approval for breast cancer drug

The U.S. Food and Drug Administration approved an Eli Lilly and Co. drug to treat advanced breast cancer that has progressed following prior treatment.

Read More »

Senators want probe of Allergan transfer deal with tribe: letter

Four U.S. senators have asked the Senate Judiciary Committee to launch an investigation into a deal drugmaker Allergan struck with a Native American tribe to protect some of its patents from generic challenge, according to a letter seen by Reuters.

Read More »

Ad Right Top


Extensive pharmaceutical business and marketing intelligence. For back issues, please contact

August 2019 Focus: AI, AR/VR, Top 200 Medicines, Lions Health Takeaways, and more!


Ad Right Bottom